This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Filippi, M. Articles by Miller, D. Search for Related Content PubMed PubMed Citation Articles by Filippi, M. Articles by Miller, D. Social Bookmarking                         What's this?

Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis

MS Biosignal Analysis Center, Department of Neurology, Scientific Institute Ospedale San Raffaele, University of Milan, Milan, Italy

F. Barkhof

MR Centre for MS Research, Department of Diagnostic Radiology, Free University Hospital, Amsterdam, The Netherlands

S. Bressi

MS Biosignal Analysis Center, Department of Neurology, Scientific Institute Ospedale San Raffaele, University of Milan, Milan, Italy

TA Yousry

Department of Diagnostic Radiology, Klinikum Grosshadern, University of Munich, Munich, Germany

DH Miller

NMR Research Unit, Institute of Neurology, University of London, London, UK

In this study we evaluated and compared the inter-rater variabilities in detecting enhancing lesions in patients with MS after injection of a standard dose (s.d.) and a triple dose (TD) of gadolinium (Gd). Enhanced magnetic resonance imaging (MRI) were obtained in 15 patients, consisting of T₁weighted images 5 to 7 min after the injection of the s.d. (0. I mmol/kg) of Gd and, after an interval of 6 to 24 h, 5 to 7 min after the injection of the TD (0.3 mmol/kg). An additional scan I h after the TD injection (delayed scanning - DS) was obtained in 11 patients. The scans were independently evaluated in a random order by four observers. Lesions were counted and scored according to size and location. The level of inter-observer concordance was very high for reporting the total numbers of enhancing lesions, their sizes and sites for the three experimental conditions. No significant differences were found in inter-observer variability in reporting the total number of enhancing lesions and their location in different brain sites in the three conditions. Our data indicate that the gain in sensitivity in detecting enhancing lesions in MS with the TD is not counteracted by a loss in reproducibility. This is important in planning clinical trials in which the number of enhancing lesions is used as a measure of outcome.

Key Words: multiple sclerosis • magnetic resonance imaging • enhancing lesions • triple dose of gadolinium • inter-observer variability

Multiple Sclerosis, Vol. 3, No. 4, 226-230 (1997)
DOI: 10.1177/135245859700300402


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Rinaldi, P. Gallo, M. Calabrese, F. Ranzato, D. Luise, D. Colavito, M. Motta, A. Guglielmo, E. Del Giudice, C. Romualdi, et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain, August 1, 2006; 129(Pt 8): 1993 - 2007. [Abstract] [Full Text] [PDF]

				M Filippi Enhanced magnetic resonance imaging in multiple sclerosis Multiple Sclerosis, October 1, 2000; 6(5): 320 - 326. [Abstract] [PDF]

				Evidence of interferon {beta}-1a dose response in relapsing-remitting MS: The OWIMS Study Neurology, September 1, 1999; 53(4): 679 - 679. [Abstract] [Full Text] [PDF]